X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
Rytelo (imetelstat) is an investigational, novel telomerase inhibitor, administered via intravenous infusion, being developed for relapsed/refractory myelofibrosis.
Lead Product(s): Imetelstat
Therapeutic Area: Oncology Product Name: Rytelo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2024
Details:
Geron will use the proceeds to fund the potential commercialization of GRN163L in low or intermediate-1 risk myelodysplastic syndromes in the U.S, and potential launch and commercialization of imetelstat in low or intermediate-1 risk myelodysplastic syndromes in the EU.
Lead Product(s): Imetelstat
Therapeutic Area: Oncology Product Name: GRN163L
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: TD Cowen
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 19, 2024
Details:
GRN163L (imetelstat) is an investigational, novel telomerase inhibitor, administered via intravenous infusion, being developed for relapsed/refractory myelofibrosis.
Lead Product(s): Imetelstat
Therapeutic Area: Oncology Product Name: GRN163L
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2023
Details:
GRN163L (imetelstat) is an investigational, novel telomerase inhibitor, by which drug inhibits the uncontrolled proliferation of malignant stem and progenitor cells in relapsed/refractory AML or higher risk MDS resulting in malignant cell apoptosis.
Lead Product(s): Imetelstat
Therapeutic Area: Oncology Product Name: GRN163L
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2023
Details:
GRN163L (imetelstat) is an investigational, novel telomerase inhibitor, by which drug inhibits the uncontrolled proliferation of malignant stem and progenitor cells in Relapsed/Refractory AML or Higher Risk MDS resulting in malignant cell apoptosis.
Lead Product(s): Imetelstat
Therapeutic Area: Oncology Product Name: GRN163L
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2023
Details:
GRN163L (imetelstat) is an investigational, novel telomerase inhibitor, by which drug inhibits the uncontrolled proliferation of malignant stem and progenitor cells in relapsed/refractory AML or higher risk MDS resulting in malignant cell apoptosis.
Lead Product(s): Imetelstat
Therapeutic Area: Oncology Product Name: GRN163L
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 21, 2023
Details:
GRN163L (imetelstat) is an investigational, novel telomerase inhibitor, by which drug inhibits the uncontrolled proliferation of malignant stem and progenitor cells in Relapsed/Refractory AML or Higher Risk MDS resulting in malignant cell apoptosis.
Lead Product(s): Imetelstat
Therapeutic Area: Oncology Product Name: GRN163L
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2023
Details:
GRN163L (imetelstat) is an investigational, telomerase inhibitor, by which drug inhibits the uncontrolled proliferation of malignant stem and investigated for the treatment of transfusion-dependent anemia with low- to intermediate-1 risk myelodysplastic syndromes.
Lead Product(s): Imetelstat
Therapeutic Area: Oncology Product Name: GRN163L
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
Details:
GRN163L (imetelstat) is an investigational, novel telomerase inhibitor, by which drug inhibits the uncontrolled proliferation of malignant stem and progenitor cells in Relapsed/Refractory AML or Higher Risk MDS resulting in malignant cell apoptosis.
Lead Product(s): Imetelstat
Therapeutic Area: Oncology Product Name: GRN163L
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2023
Details:
GRN163L (imetelstat) is an investigational, novel telomerase inhibitor, by which drug inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies resulting in malignant cell apoptosis.
Lead Product(s): Imetelstat
Therapeutic Area: Oncology Product Name: GRN163L
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2023
Details:
Geron currently intends to use the net proceeds from this public offering to fund preparatory activities for the potential U.S. commercial launch of GRN163L (imetelstat) in lower risk MDS, and, if approved, to fund the potential U.S. commercial launch of imetelstat.
Lead Product(s): Imetelstat
Therapeutic Area: Oncology Product Name: GRN163L
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Goldman Sachs & Co.
Deal Size: $227.8 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 10, 2023
Details:
GRN163L (imetelstat) is a first-in-class telomerase inhibitor. Imetelstat binds to telomerase and inhibits its activity, selectively killing the malignant stem and progenitor cells in the bone marrow that are the source of disease in blood cancers.
Lead Product(s): Imetelstat
Therapeutic Area: Oncology Product Name: GRN163L
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Goldman Sachs
Deal Size: $175.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 04, 2023
Details:
GRN163L (Imetelstat), is a novel, first-in-class telomerase inhibitor is being developed in hematologic malignancies. Drug inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies resulting in malignant cell apoptosis.
Lead Product(s): Imetelstat
Therapeutic Area: Oncology Product Name: GRN163L
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2023
Details:
GRN163L (Imetelstat) binds to telomerase and inhibits its activity, selectively killing the malignant stem and progenitor cells in the bone marrow that are the source of disease in blood cancers, such as myelodysplastic syndromes (MDS) and myelofibrosis (MF).
Lead Product(s): Imetelstat
Therapeutic Area: Oncology Product Name: GRN163L
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2023
Details:
The abstract describes results from non-clinical in vitro and animal in vivo experiments of imetelstat (GRN163L) using AML cell lines and AML patient samples.
Lead Product(s): Imetelstat
Therapeutic Area: Oncology Product Name: GRN163L
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
Single-agent GRN163L (imetelstat) currently being studied in a separate Phase 3 trial designed to confirm clinically meaningful benefits observed in relapsed/refractory MF patients in Phase 2 study.
Lead Product(s): Imetelstat,Ruxolitinib Phosphate
Therapeutic Area: Oncology Product Name: GRN163L
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
Details:
Geron currently intends to use the net proceeds, together with its existing cash, cash equivalents, restricted cash and marketable securities to fund potential regulatory lings in the United States and European Union for imetelstat in lower risk myelodysplastic syndromes.
Lead Product(s): Imetelstat
Therapeutic Area: Oncology Product Name: GRN163L
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Stifel
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 30, 2022
Details:
Phase 2 clinical trials provide strong evidence that imetelstat targets telomerase to inhibit the uncontrolled proliferation of malignant stem & progenitor cells in hematologic myeloid malignancies resulting in malignant cell apoptosis & potential disease-modifying activity.
Lead Product(s): Imetelstat
Therapeutic Area: Oncology Product Name: GRN163L
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2021
Details:
Data from the abstracts support ongoing Phase 3 trial in lower risk MDS and the upcoming Phase 3 trial in refractory MF and highlight the clinical benefits and the potential disease-modifying activity achievable with imetelstat treatment.
Lead Product(s): Imetelstat
Therapeutic Area: Oncology Product Name: GRN163L
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
Details:
This debt financing strengthens the company's balance sheet and provides additional financial flexibility as our imetelstat program advances with two Phase 3 registration-enabling clinical trials.
Lead Product(s): Imetelstat
Therapeutic Area: Oncology Product Name: GRN163L
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Hercules Capital
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Financing October 01, 2020
Details:
European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinion on the Company’s application for orphan drug designation of its first-in-class telomerase inhibitor, imetelstat, as a potential treatment for myelodysplastic syndromes.
Lead Product(s): Imetelstat
Therapeutic Area: Oncology Product Name: GRN163L
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2020
Details:
For the IMerge Phase 2 clinical trial, meaningful and durable transfusion independence reported with a new 1-year TI rate, indicating potential disease-modifying activity of imetelstat treatment.
Lead Product(s): Imetelstat
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2020
Details:
Geron plans to move forward with a Phase 3 clinical trial in refractory myelofibrosis with overall survival as a primary endpoint, which is expected to open for screening and enrollment.
Lead Product(s): Imetelstat
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
